These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 31837884)

  • 41. The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
    Gurin D; Slavik M; Hermanova M; Selingerova I; Kazda T; Hendrych M; Shatokhina T; Vesela M
    J Oral Pathol Med; 2020 Oct; 49(9):886-896. PubMed ID: 32516834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer.
    Birtalan E; Danos K; Gurbi B; Brauswetter D; Halasz J; Kalocsane Piurko V; Acs B; Antal B; Mihalyi R; Pato A; Fent Z; Polony G; Timar J; Tamas L
    Appl Immunohistochem Mol Morphol; 2018 Aug; 26(7):e79-e85. PubMed ID: 29271789
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
    Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
    Chen SW; Li SH; Shi DB; Jiang WM; Song M; Yang AK; Li YD; Bei JX; Chen WK; Zhang Q
    Int J Biol Markers; 2019 Dec; 34(4):398-405. PubMed ID: 31674884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.
    Kim HS; Lee JY; Lim SH; Park K; Sun JM; Ko YH; Baek CH; Son YI; Jeong HS; Ahn YC; Lee MY; Hong M; Ahn MJ
    Cancer Res Treat; 2016 Apr; 48(2):527-36. PubMed ID: 26511814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value and clinicopathological status of PD-L1 expression and CD8+ TILs in oral squamous cell cancer patients with or without traditional risk factors.
    Soopanit T; Laokulrath N; Chayopasakul V; Pongsapich W
    Head Neck; 2023 Apr; 45(4):1017-1025. PubMed ID: 36811208
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma.
    Jeong JY; Park TI; Ahn D
    Anticancer Res; 2020 Jul; 40(7):4001-4010. PubMed ID: 32620644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes.
    De Meulenaere A; Vermassen T; Aspeslagh S; Zwaenepoel K; Deron P; Duprez F; Rottey S; Ferdinande L
    Pathology; 2017 Jun; 49(4):397-404. PubMed ID: 28427753
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking.
    Lilja-Fischer JK; Eriksen JG; Georgsen JB; Vo TT; Larsen SR; Cheng J; Busch-Sørensen M; Aurora-Garg D; Steiniche T; Overgaard J
    Acta Oncol; 2020 Jun; 59(6):666-672. PubMed ID: 32079442
    [No Abstract]   [Full Text] [Related]  

  • 50. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
    Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High PD-L1 expression associates with low T-cadherin expression and poor prognosis in human papillomavirus-negative head and neck squamous cell carcinoma.
    Wang Q; Zhao Y; Chen Y; Chen Y; Song X; Zhang L; He Q; Ye B; Wu L; Huang X; Wang D
    Head Neck; 2023 May; 45(5):1162-1171. PubMed ID: 36939297
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PD-L1 immunohistochemical expression considering HPV status in oropharyngeal squamous cell carcinoma.
    Anjos RSD; Carvalho MV; Costa RTF; Vasconcelos BCDE; Moraes SLD; Pellizzer EP
    Braz Oral Res; 2024; 38():e095. PubMed ID: 39356903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lectin-like Transcript-1 (LLT1) Expression in Oral Squamous Cell Carcinomas: Prognostic Significance and Relationship with the Tumor Immune Microenvironment.
    de Vicente JC; Lequerica-Fernández P; Rodrigo JP; Rodríguez-Santamarta T; Blanco-Lorenzo V; Prieto-Fernández L; Corte-Torres D; Vallina A; Domínguez-Iglesias F; Álvarez-Teijeiro S; García-Pedrero JM
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673902
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
    Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
    Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
    Chang SR; Chou CH; Liu CJ; Lin YC; Tu HF; Chang KW; Lin SC
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983005
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
    Oguejiofor K; Galletta-Williams H; Dovedi SJ; Roberts DL; Stern PL; West CM
    Oncotarget; 2017 Feb; 8(9):14416-14427. PubMed ID: 28122336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Study of the PD-L1 expression, T-cells density and immunoscore in paired baseline tumor biopsies and surgical specimens in squamous cell carcinoma of the oral cavity.
    Beyaert S; Borys A; Baldin P; Dahou H; Magremanne M; Mahy P; Renwart W; Machiels JP; Schmitz S
    Oral Oncol; 2024 Jul; 154():106869. PubMed ID: 38820890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma.
    Blatt S; Krüger M; Rump C; Zimmer S; Sagheb K; Künzel J
    PLoS One; 2022; 17(5):e0269136. PubMed ID: 35622885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.